CKD-351
- Generic Name
- CKD-351
Study to Evaluate Drug-drug Interaction, Safety and Tolerability in Case of the Co-administration of D565 and D930
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2023-01-05
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 32
- Registration Number
- NCT05207761
- Locations
- 🇰🇷
Seoul National University College of Medicine and Hospital, Seoul, Korea, Republic of
A Clinical Study to Evaluate the Efficacy and Safety of CKD-351
Phase 2
- Conditions
- Primary Open Angle GlaucomaOcular Hypertension
- Interventions
- Drug: Latanoprost+Dorzolmamide
- First Posted Date
- 2020-06-25
- Last Posted Date
- 2020-06-25
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 100
- Registration Number
- NCT04448223
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
A Clinical Study to Evaluate the Efficacy and Safety of CKD-351
Phase 3
- Conditions
- Primary Open-angle GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2018-12-03
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 384
- Registration Number
- NCT03762369
- Locations
- 🇰🇷
Seoul National University Hosipital, Seoul, Jongno, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath